Simultaneous integrated boost and protection proton beam therapy approach for hepatocellular carcinoma.
기술보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
47 patients with HCC who underwent SIB-PBT between 2014-2021.
I · Intervention 중재 / 시술
SIB-PBT between 2014-2021
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
CP + 2 occurred in 5 patients. [CONCLUSION] SIB-PBT enables OAR protection along with heterogeneous tumor dose escalation and is a safe and effective treatment for HCC tumors.
[PURPOSE] Although simultaneous integrated boost and protection with proton beam therapy (SIB-PBT) facilitates tumor dose escalation while maintaining organ-at-risk (OAR) dose constraints, clinical ou
- 표본수 (n) 22
- 95% CI 4.7-23.4
- 추적기간 22 months
APA
Thonglert K, Greer MD, et al. (2025). Simultaneous integrated boost and protection proton beam therapy approach for hepatocellular carcinoma.. Clinical and translational radiation oncology, 54, 101008. https://doi.org/10.1016/j.ctro.2025.101008
MLA
Thonglert K, et al.. "Simultaneous integrated boost and protection proton beam therapy approach for hepatocellular carcinoma.." Clinical and translational radiation oncology, vol. 54, 2025, pp. 101008.
PMID
40778089 ↗
Abstract 한글 요약
[PURPOSE] Although simultaneous integrated boost and protection with proton beam therapy (SIB-PBT) facilitates tumor dose escalation while maintaining organ-at-risk (OAR) dose constraints, clinical outcomes are limited. This study assessed the safety and efficacy of using the SIB-PBT technique in hepatocellular carcinoma (HCC) patients.
[METHODS] We reviewed 47 patients with HCC who underwent SIB-PBT between 2014-2021. The radiation dose ranged from 36-67.5 Gy(RBE) in 15 fractions. SIB-PBT was used for the following reasons: minimize high-dose exposure to organs-at-risk (OARs) (n = 22, 47 %), treat targets with different dose levels (n = 6, 13 %), or both (n = 19, 40 %). Survival, local control, and toxicities were assessed using Kaplan-Meier, Fine-Gray cumulative incidence, and descriptive statistics, respectively.
[RESULTS] Forty-one patients (87 %) had tumors located ≤2 cm from luminal gastrointestinal (GI) OARs. The median tumor diameter was 9.2 cm (range, 2.0-21.5 cm). The median EQD2 D50%, D95% and D99% of gross tumor volume were 79.8 (range, 51.1-85.9), 66.7 (range, 36.9-84.6) and 50.2 (range, 34.1-83.6) Gy(RBE), respectively. Most patients (91 %) received a D0.5 cc of <45 Gy(RBE) to luminal GI OARs. At a median follow-up of 22 months (range, 0.8-77.0 months), the 2-year cumulative incidence of local failure was 12 %. The 2-year progression-free survival and overall survival rates were 12 % (95 % CI 4.7-23.4 %), and 49 % (95 % CI, 33.2-63.2 %), respectively. One patient experienced grade 3 acute nausea/vomiting. No GI bleeding/ulcers or grade 4 + toxicity were observed. CP + 2 occurred in 5 patients.
[CONCLUSION] SIB-PBT enables OAR protection along with heterogeneous tumor dose escalation and is a safe and effective treatment for HCC tumors.
[METHODS] We reviewed 47 patients with HCC who underwent SIB-PBT between 2014-2021. The radiation dose ranged from 36-67.5 Gy(RBE) in 15 fractions. SIB-PBT was used for the following reasons: minimize high-dose exposure to organs-at-risk (OARs) (n = 22, 47 %), treat targets with different dose levels (n = 6, 13 %), or both (n = 19, 40 %). Survival, local control, and toxicities were assessed using Kaplan-Meier, Fine-Gray cumulative incidence, and descriptive statistics, respectively.
[RESULTS] Forty-one patients (87 %) had tumors located ≤2 cm from luminal gastrointestinal (GI) OARs. The median tumor diameter was 9.2 cm (range, 2.0-21.5 cm). The median EQD2 D50%, D95% and D99% of gross tumor volume were 79.8 (range, 51.1-85.9), 66.7 (range, 36.9-84.6) and 50.2 (range, 34.1-83.6) Gy(RBE), respectively. Most patients (91 %) received a D0.5 cc of <45 Gy(RBE) to luminal GI OARs. At a median follow-up of 22 months (range, 0.8-77.0 months), the 2-year cumulative incidence of local failure was 12 %. The 2-year progression-free survival and overall survival rates were 12 % (95 % CI 4.7-23.4 %), and 49 % (95 % CI, 33.2-63.2 %), respectively. One patient experienced grade 3 acute nausea/vomiting. No GI bleeding/ulcers or grade 4 + toxicity were observed. CP + 2 occurred in 5 patients.
[CONCLUSION] SIB-PBT enables OAR protection along with heterogeneous tumor dose escalation and is a safe and effective treatment for HCC tumors.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
- Safety and Efficacy of External Beam Radiation Therapy in Hepatocellular Carcinoma Patients Previously Treated With Yttrium 90 Transarterial Radioembolization.
- Establishing Albumin-Bilirubin Score Changes as Predictors of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Post-External Beam Radiation Therapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Intra-procedural Cone-Beam Computed Tomography for Ultrasound-Guided Microwave Ablation of Hepatocellular Carcinoma: An Initial Experience.
- Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention.
- DDX17-mediated raptor-dependent mTORC1 activation links autophagy inhibition and metabolic compensation in HCC development.
- Combinatorial treatment with donafenib and quercetin suppresses lipid metabolism in HepG2 cells by targeting the CREB1/DRP1/SREBP1 axis.
- Integrated Transcriptomic and Histological Analysis of TP53/CTNNB1 Mutations and Microvascular Invasion in Hepatocellular Carcinoma.
- Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomes.